Clinical trial · Interventional
Unrelated Donor Stem Cell Transplantation
Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors
NCT01364363CI-TRIAL-00062335completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.
Conditions
Conditions (13)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Chronic Myelogenous Leukemia | Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Hodgkin's Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
| Large Granulocytic Leukemia | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| Myeloproliferative Syndromes | — | UNRESOLVED |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allogeneic transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- type
- OTHER
- label
- Total Body Irradiation/VP16
- description
- Acute Leukemias, Myelodysplastic syndromes
- interventionNames
- Procedure: Allogeneic transplantation
- type
- OTHER
- label
- Cytoxan/Total Body Irradiation
- description
- Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
- interventionNames
- Procedure: Allogeneic transplantation
- type
- OTHER
- label
- Busulfan/Cytoxan
- description
- Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years of Age * \< 70 years * ECOG performance status 0, 1 or 2 * Left Ventricular Ejection Fraction \> 30% * Creatinine clearance \> 40ml/min * Transaminases \< 2X normal * Total bilirubin \< 2X normal * HIV seronegativity * Weight \< 70kg for cord blood transplantation * Ability to cover the cost of the transplant, necessary medications, and transportation/housing. * Caregiver must be available while outpatient Exclusion Criteria: * Greater than one antigen mismatch at HLA-A, B, C or DR plus one allele mismatch at HLA-A, B, C or DR
References
Publications (0)
Data not yet available
No reference posted for this study.